Opdivo Overtakes Keytruda, Fueled By Lung Cancer Use
This article was originally published in Scrip
Executive Summary
Thanks in part to a new indication in lung cancer and despite a later start on the market, Bristol-Myers Squibb Co.'s anti-PD1 Opdivo tripled its sequential sales in the second quarter, edging ahead of Merck & Co. Inc.'s competing Keytruda.